Group 1 - The company, 康基医疗, and the offeror, Knight Bidco Limited, announced a privatization plan to allow the company to focus on long-term strategic decisions, including R&D investments and operational upgrades [1] - The proposed cancellation price is set at HKD 9.25 per share, representing a premium of approximately 21.7% over the closing price of HKD 7.6 as of the undisturbed date (June 30, 2025) [1] - The cancellation price also reflects a premium of about 29.7% over the average closing price of HKD 7.13 per share for the 120 trading days prior to the undisturbed date, and a premium of approximately 47.3% over the average closing price of HKD 6.28 per share for the 360 trading days prior [1] Group 2 - The privatization cash consideration amounts to approximately HKD 58.2 billion, and the offeror does not reserve the right to increase the cancellation price [2] - The offeror is backed by a consortium that includes alternative asset management company TPG [2] - 康基医疗 resumed trading today after being suspended since July 18 [2]
康基医疗获由董事长钟鸣牵头财团溢价提私有化，今日复牌